Delivery Order SPE2DB22D2006-SPE2DB25FW4CJ
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,162.70 for Mounjaro 5 mg/0.5 mL pen injectors on August 20, 2025, with completion expected by August 21, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2 diabetes. This delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,162.70 for Mounjaro 7.5 mg/0.5 ml pen auto-injectors on July 23, 2025, with completion targeted for July 24, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, representing part of the company's...
- The Defense Logistics Agency awarded a $6,045.27 delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injections on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication, consistent with AmerisourceBergen's established portfolio of...
- The Defense Logistics Agency awarded a delivery order valued at $45,830.70 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pen injectors (0.5 mL units). This firm fixed-price delivery order, awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive award under an existing contract vehicle. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is...
- The Defense Logistics Agency awarded a $1,088.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Mounjaro 10 mg/0.5 mL pen injectors. This is a non-set-aside competitive award with an ultimate completion date of August 12, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in patients with type 2 diabetes, and this delivery order...
- The Defense Logistics Agency awarded a $2,777.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injectors on September 8, 2025, with completion targeted for September 9, 2025. This delivery order, issued without a set-aside designation, represents a competitive award under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $3,057.94 to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injectors on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes treatment medication, consistent with AmerisourceBergen's extensive...
- The Defense Logistics Agency awarded a delivery order valued at $14,094.91 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was awarded competitively with no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Mounjaro is a diabetes management medication, consistent with AmerisourceBergen's established...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $5,758.57 firm fixed-price delivery order on August 14, 2025, for Mounjaro 2.5 mg/0.5 mL pen injections, with an ultimate completion date of August 15, 2025. The contract, issued without set-aside designation, represents a competitively awarded procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $1,360.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract, which carries no set-aside designation, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4CJDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $45,099.00 for Mounjaro 5 mg/0.5 mL pen injections on September 9, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied to federal healthcare systems. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's status as a major pharmaceutical distributor and critical federal medical procurement vendor is evidenced by its consistent receipt of competitive awards across multiple therapeutic domains, positioning it as a primary supplier for Department of Defense medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $45.1k | 9/9/25 |